A Phase 3 interventional study of Intravenous tirofiban before endovascular thrombectomy and Intravenous placebo before endovascular thrombectomy in Stroke, Ischemic, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by General Hospital of Shenyang Military Region · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 5th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 5 of the 15 other live ones, and was the 28th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 5
First in 2016; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 870 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 145 across the 27 interventional studies, 1,000 across the 7 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
11 of the studies in Ischemic Stroke by General Hospital of Shenyang Military Region that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07135089Phase 3General Hospital of Shenyang Military RegionImproving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban | 2027-09-30 |
| NCT06170944General Hospital of Shenyang Military RegionEffect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07344610General Hospital of Shenyang Military RegionEffects of Short-term Intensive Statin Therapy on Lipid Levels | 2026-12-30 |
| NCT06940128General Hospital of Shenyang Military RegionDirect Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO) | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous tirofiban before endovascular thrombectomy
Drug: Intravenous tirofiban before endovascular thrombectomy
Intravenous placebo before Endovascular Thrombectomy
Drug: Intravenous placebo before endovascular thrombectomy
The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
The proportion of patients with functional independence (modified Rankin Scale [mRS] score of 0 to 2)
mRS ranges from 0-6, with high score meaning poor outcome
Time frame: Day 90
The proportion of patients without disability (modified Rankin Scale [mRS] score of 0 to 1) or who returned to their premorbid mRS score at 90 days (for patients with prestroke mRS score >1)
mRS ranges from 0-6, with high score meaning poor outcome
Time frame: Day 90
ordinal distribution of modified Rankin Scale (mRS)
mRS ranges from 0-6, with high score meaning poor outcome
Time frame: Day 90
The proportions of patients with substantial reperfusion at initial preprocedure catheter angiogram (defined as mTICI score ≥2b)
Substantial reperfusion was defined as an expanded Thrombolysis In Cerebral Infarction grade of 2b50 (substantial reperfusion), 2c (nearcomplete reperfusion), or 3 (complete reperfusion).
Time frame: immediately after first catheter angiogram
The proportions of patients with substantial reperfusion at final angiogram
Time frame: immediately after final angiogram
The proportions of patients with complete recanalization as assessed by CTA or MRA 48 hours after endovascular treatment
Time frame: 24 (-6/+24) hours
Change in National Institute of Health stroke scale (NIHSS)
NIHSS ranges from 0-42, with high score meaning poor outcome
Time frame: 24 (-6/+24) hours
change in National Institute of Health stroke scale (NIHSS)
NIHSS ranges from 0-42, with high score meaning poor outcome
Time frame: 7 (-2/+2) days
The incidence of symptomatic intracranial hemorrhage assessed according to Heidelberg bleeding classification
Time frame: 24 (-6/+24) hours
The incidence of intraparenchymal hemorrhage (PH1 and PH2)
Time frame: 24 (-6/+24) hours
The incidence of non-intracranial hemorrhage complications
Time frame: 24 (-6/+24) hours
Serious adverse events
eg, acute respiratory failure, large or malignant middle cerebral artery infarction, acute heart failure, hemicraniectomy
Time frame: 7 (-2/+2) days
Procedure-associated complications
Time frame: Periprocedural
The proportion of patients with thrombocytopenia
Time frame: 24 (-6/+24) hours
The incidence of mortality
Time frame: Day 90
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 22 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region